We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of HIV-associated Kaposi's sarcoma with paclitaxel.
- Authors
Saville, M W; Lietzau, J; Pluda, J M; Feuerstein, I; Odom, J; Wilson, W H; Humphrey, R W; Feigal, E; Steinberg, S M; Broder, S
- Abstract
We investigated whether paclitaxel was active in AIDS-associated Kaposi's sarcoma. We gave 135 mg/m2 intravenously over 3 hours every 21 days. Follow-up is available on the first 20 patients, most of whom had advanced Kaposi's sarcoma and severe immunocompromise. Neutropenia was the most frequent dose-limiting toxic effect; novel toxic effects included late fevers, rash, and eosinophilia. Creatinine increased in 2 patients and 1 patient had cardiomyopathy. There were 13 partial responses (65%, 95% CI 41-85%). All 5 patients with pulmonary involvement responded. Paclitaxel appears to be active against Kaposi's sarcoma as a single agent. Further studies, including a randomised trial, are warranted.
- Publication
Lancet (London, England), 1995, Vol 346, Issue 8966, p26
- ISSN
0140-6736
- Publication type
Journal Article
- DOI
10.1016/s0140-6736(95)92654-2